Recently, Liang Jian, Chairman and General Manager of Nanjing Pharmacare Technology Co., Ltd., was invited to attend the "Tea House Discussion on Pharmaceutical Companies Going Global" industry symposium in the pharmaceutical finance circle, and explored the globalization opportunities of Chinese pharmaceutical companies with executives from companies such as Sinovac Biotech, Amphenol Pharmaceuticals, and Shanghai Pharmaceuticals. As one of the pioneers in the internationalization of Chinese medicine, Pharmacare shared key practical experience at the conference and reached multiple consensuses with industry partners.
1. Brazilian benchmark: Local operation breaks through barriers
Pharmacare takes Brazil as its strategic pivot, overcomes strict regulations (such as bioequivalence testing) through localized teams, precise product selection, and supply chain optimization, and maintains a leading market share in multiple categories in the Brazilian market, becoming the vanguard of Chinese generic drugs going global to Brazil.
2. One stop platform empowers partners
Relying on the full chain capability of "product selection registration production sales", Pharmacare assists partners in covering over 60 international markets, with a focus on expanding into emerging regions such as Southeast Asia and the Middle East. Mr. Liang emphasized, "Matching technological barriers with market demand is the core of successful overseas expansion
3. Accelerated layout in Europe
The landing of the Dutch subsidiary is driving breakthroughs in the European market, and the first MA is about to be approved. In the future, we will expand our specialty formulations. Mr. Liang pointed out, "Europe tests the ability to balance scientific registration with long-term investment
Sinovac
Sharing the experience of the European market, emphasizing that "complex formulations need to be benchmarked against original research in terms of quality and respond quickly to shortage demands".
Anbisheng Pharmaceutical
Propose a "flexible cooperation model" to address the dispersed channels in emerging markets, such as reducing bidding costs through local alliances.
Shanghai Pharmaceutical
Focusing on Southeast Asian layout, it is mentioned that "brand drug promotion+localization team" is the key to seizing the mid to high end market.
Pharmacare
Taking Brazil as an example, analyze how "supply chain resilience+local testing" can solve the problem of emerging market access.
Consensus and Action
Consensus and action: Long termism is the foundation of breaking through
The attending companies unanimously agree that Chinese pharmaceutical companies need to face three major challenges when going global:
1. Regulatory differences: Emerging markets require "one country, one policy" and require a deep understanding of local drug regulatory logic.
2. Localized cultivation: From registration to sales, a localized team is the foundation for long-term rooting.
3. Supply chain resilience: The entire process of sea freight cycle, warehouse inspection, etc. needs to be controlled.
Future prospects
Mr. Liang summarized: "Going global is a ten-year journey of sharpening a sword. Only by focusing on differentiated product selection, scientific registration, and localized operation can we build sustainable competitiveness." Pharmacare is willing to work together with industry partners to jointly build a new global ecosystem for Chinese pharmaceutical companies.
2025 Join hands and explore the blue ocean together
Pharmacare cordially invites partners to share international resources and experience, empowering Chinese pharmaceutical companies to expand globally.
*Source: Compiled from the content of the "Tea House Talks about Pharmaceutical Companies Going Global" symposium in the pharmaceutical finance circle
*Disclaimer *: The information in this article is based on industry exchanges and is intended to provide reference value and does not constitute any investment or decision-making advice. This official account will not be liable for the direct or indirect losses caused by the use of this content. If there is a copyright or expression dispute, please contact us through the backend and we will handle it as soon as possible.
*Reprint statement *: welcome to forward and share and quote reasonably. When quoting, please mark the source "Nanjing Pharmacare official account"; If you need to reprint the full text, please leave a message at the back of the official account to apply for authorization, and indicate the name of the official account and the title of the reprinted article.
Japanese
Chinese
Spanish